Skip to main content
Clinical Trials/NCT04915456
NCT04915456
Completed
Phase 4

Prospective Randomized, Placebo-controlled Clinical Study to Study the Effect of Postoperative Additive Systemic Steroids in Chronic Rhinosinusitis With Nasal Polyps

Friedrich-Alexander-Universität Erlangen-Nürnberg0 sites106 target enrollmentJanuary 18, 2005

Overview

Phase
Phase 4
Intervention
Systemic Steroid (Prednisolone)
Conditions
Sinusitis, Chronic
Sponsor
Friedrich-Alexander-Universität Erlangen-Nürnberg
Enrollment
106
Primary Endpoint
Nasal Polyp Score (NPS)
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This study investigate the additive effect of systemic postoperative steroids in patients with chronic rhinosinusitis (CRSwNP). All patients receive a functional endoscopic sinus surgery (FESS) followed by topical steroid spray for 3 months. Postoperatively, patients will be randomized to either an additional systemic steroid or a placebo for 1 month. Patients will be followed for 2 years. Effect on Nasal Polyp score (NPS), Lund-Kennedy-Score (LKS), recurrence rates, smell scores, Rhinosinusitis Disability Index (RSDI), Short-Form 36 (SF-36) and mucus/serum biomarkers will be measured.

Registry
clinicaltrials.gov
Start Date
January 18, 2005
End Date
February 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sarina Mueller

PD Dr. med.

Friedrich-Alexander-Universität Erlangen-Nürnberg

Eligibility Criteria

Inclusion Criteria

  • refractory to medical therapy
  • no previous sinus surgery
  • Lund-Kennedy-Score ≥ 1
  • Lund-Mackay-Score ≥ 10

Exclusion Criteria

  • ciliary impairment
  • autoimmune disease
  • cystic fibrosis
  • immunodeficiency

Arms & Interventions

Systemic steroid (Prednisolone)

Prednisolone 50mg (tapered down until postoperative day (POD) 14, then 5mg for 14 days), tablets

Intervention: Systemic Steroid (Prednisolone)

Placebo

Lactose monohydrate, tablets

Intervention: Placebo

Outcomes

Primary Outcomes

Nasal Polyp Score (NPS)

Time Frame: first visit until 24 months, change is measured between baseline and each follow-up time point up to 24 months (follow-up time points are as follows: 3 weeks, 3 months, 6 months, 9 months, 12 months, 18 months)

Each nostril will be assessed separately. The highest score will be graded. Each nostril will be scored from 0-4 (0=no polyps, 1=polyps confined to the middle meatus, 3=polyps extending beyond middle meatus, 4=large polyps causing almost complete nasal obstruction)

Secondary Outcomes

  • Lund-Kennedy-Score (LKS)(first visit until 24 months, change is measured between baseline and each follow-up time point up to 24 months (follow-up time points are as follows: 3 weeks, 3 months, 6 months, 9 months, 12 months, 18 months))
  • Smell Scores(first visit until 24 months, change is measured between baseline and each follow-up time point up to 24 months (follow-up time points are as follows: 3 weeks, 3 months, 6 months, 9 months, 12 months, 18 months))
  • Sinonasal Symptom Score(first visit until 24 months, change is measured between baseline and each follow-up time point up to 24 months (follow-up time points are as follows: 3 weeks, 3 months, 6 months, 9 months, 12 months, 18 months))
  • Mucus and serum biomarker levels(first visit until 24 months, change is measured between baseline and each follow-up time point up to 24 months (follow-up time points are as follows: 3 weeks, 3 months, 6 months, 9 months, 12 months, 18 months))
  • RSDI (Rhinosinusitis Disability Index)(first visit until 24 months, change is measured between baseline and each follow-up time point up to 24 months (follow-up time points are as follows: 3 weeks, 3 months, 6 months, 9 months, 12 months, 18 months))
  • SF-36 (Short Form-36)(first visit until 24 months, change is measured between baseline and each follow-up time point up to 24 months (follow-up time points are as follows: 3 weeks, 3 months, 6 months, 9 months, 12 months, 18 months))
  • Recurrence rates(first visit until 24 months, change is measured between baseline and each follow-up time point up to 24 months (follow-up time points are as follows: 3 weeks, 3 months, 6 months, 9 months, 12 months, 18 months))

Similar Trials